WASHINGTON, Oct 24 (Reuters) - Liver problems linked to Abbott Laboratories Inc.'s (ABT.N: Quote, Profile, Research) discontinued attention deficit drug Cylert and other generic versions make the drug too dangerous for the U.S. market, the Food and Drug Administration said on Monday.
